-+ 0.00%
-+ 0.00%
-+ 0.00%
Strengthen CNS Trial Outcomes Through Smarter Data Capture, Upcoming Webinar Hosted by Xtalks
Share
Listen to the news

In this free webinar, learn how smarter data capture strategies can improve data quality and study efficiency in central nervous system (CNS) clinical trials. The featured speakers will discuss challenges such as site burden, rater variability, patient fatigue and cognitive limitations, along with approaches to patient and caregiver engagement. Attendees will also explore electronic clinical outcome assessment (eCOA) best practices, including intuitive interfaces, rater guidance and real-time data monitoring.

TORONTO, Nov. 12, 2026 /PRNewswire/ -- Central nervous system (CNS) research presents unique challenges, requiring the capture of multiple types and formats of data from clinicians, patients, caregivers and performance-based assessments. These complexities can affect data quality, participant engagement and study efficiency. This webinar will bring together perspectives from a CNS sponsors, investigators and patient-centric technology providers to examine common data capture challenges and practical approaches to addressing them.

www.xtalks.com

CNS studies often involve complex assessments, diverse data sources and participants with cognitive or functional limitations. Challenges such as site burden, rater variability and patient fatigue can affect the consistency and completeness of collected data. Understanding these factors is essential for developing effective data collection strategies that support reliable study outcomes.

The session will explore how electronic clinical outcome assessments (eCOA) can support patient and caregiver engagement, improve assessment consistency and facilitate more efficient data capture. Attendees will gain insights into best practices, including intuitive interfaces, built-in rater guidance and real-time data monitoring, that can help improve data quality and streamline CNS clinical trial workflows.

Register for this webinar to learn how effective data capture strategies and eCOA best practices can improve data quality, participant engagement and operational efficiency in CNS clinical trials.

Join Bruce Hellman, Chief Patient Officer and Co-Founder, uMotif; Florence Mowlem, PhD, Chief Scientific Officer, uMotif; Elan Cohen, PhD, Principal Investigator, CenExel; and Anne-Marie Li-Kwai-Cheung, Chief Development Officer, Neurvati Neurosciences, for the live webinar on Thursday, December 3, 2026, at 12pm EST (6pm CET).

For more information, or to register for this event, visit Strengthen CNS Trial Outcomes Through Smarter Data Capture.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:

Soumya Shashikumar

Tel: +1 (416) 977-6555 x371

Email: skumar@xtalks.com

www.umotif.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/strengthen-cns-trial-outcomes-through-smarter-data-capture-upcoming-webinar-hosted-by-xtalks-302937244.html

SOURCE Xtalks

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending